PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Birmingham Acute Care Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.\', \'Department of Critical Care Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.\', \'Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK b.fisher@bham.ac.uk.\', \'Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.\', \'Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.\', \'National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.\', \'Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.\', \'Department of Respiratory Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.\', \'Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK.\', \'Department of Infectious Diseases, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.\', \'Oxford Clinical Trials Research Unit, Botnar Research Centre, University of Oxford, Oxford, UK.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1136/bmjopen-2021-050202
?:hasPublicationType
?:journal
  • BMJ open
is ?:pmid of
?:pmid
?:pmid
  • 34764169
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.372
?:rankingScore_hIndex
  • 57
?:title
  • CATALYST trial protocol: a multicentre, open-label, phase II, multiarm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all